Answers are grounded in this paper and cite their sources.
To investigate, through post hoc analysis of nine studies from the SemaglUtide Real-world Evidence (SURE) programme, the safety of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) and in subpopulations in routine clinical practice, complementing findings from the phase 3 randomized clinical trial (RCT) SUSTAIN programme.
No takes yet. Share an insight, caveat, or question.
Yale et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: